Hepacyl Therapeutics

Hepacyl Therapeutics is a French biotechnology company dedicated to the discovery and development of novel treatments for chronic liver diseases, particularly Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's research focuses on small molecule therapeutics designed to address the complex pathophysiology of liver inflammation and fibrosis. Founded by serial entrepreneur Dr. Philippe Halfon, Hepacyl leverages deep clinical expertise in hepatology to advance its pipeline. The company is based in Marseille and operates as a private entity within the French life sciences sector. Its lead programs target specific metabolic and inflammatory pathways to halt or reverse disease progression.